CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer / Chiorean, ; E., G.; Von, Hoff; D., D.; Reni, M; Arena, ; F., P.; Infante, ; J., R.; Bathini, ; V., G.; Wood, ; T., E.; Mainwaring, ; P., N.; Muldoon, ; R., T.; Clingan, ; P., R.; Kunzmann, ; Ramanathan, ; R., K.; Tabernero, ; Goldstein, ; Mcgovern, ; Lu, ; Ko,. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - (2016).